Assessing Dexmedetomidin's Efficacy in Traumatic Brain Injury Treatment Using a Rat Experimental Model

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Dexmedetomidine (DEX), a selective α-2 adrenergic agonist, exhibits anti-inflammatory, antioxidant, and anti-apoptotic properties.
• Limited research exists on DEX's effects following traumatic brain injury (TBI).

Purpose of the Study:

• To investigate the therapeutic effects of nasal (DexN) and intraperitoneal (DexP) DEX administration in a TBI animal model.
• To explore the underlying mechanisms of DEX's neuroprotective actions post-TBI.

Main Methods:

• Experimental TBI induced via weight-drop in 31 Wistar albino rats.
• Administration of DexN and DexP on day of trauma and day 5.
• Neurological assessment using the Garcia test.
• Histopathological and biochemical analyses (NSE, S-100B, CASP3, GSH-PX, TBARS).

Main Results:

• Treatment groups showed improved neurological outcomes (higher Garcia scores, p < 0.001).
• Intraperitoneal DEX demonstrated superior anti-inflammatory and neuroprotective effects compared to nasal DEX (p < 0.001).
• Nasal DEX reduced NSE levels (p = 0.023), indicating reduced neuronal damage. CASP3 levels decreased, and GSH-PX levels increased, suggesting neuroprotection and antioxidant effects, respectively (though not statistically significant for the latter).

Conclusions:

• Dexmedetomidine (DEX) exhibits potential therapeutic benefits for TBI.
• DEX's anti-inflammatory, antioxidant, and neuroprotective properties contribute to its efficacy.
• Further research is warranted to fully elucidate DEX's role in TBI management.